Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

39 results about "Leptin receptor" patented technology

Leptin receptor, also known as LEP-R or OB-R, is a type I cytokine receptor, a protein that in humans is encoded by the LEPR gene. LEP-R functions as a receptor for the fat cell-specific hormone leptin. LEP-R has also been designated as CD295 (cluster of differentiation 295). Its location is the cell membrane, and it has extracellular, trans-membrane and intracellular sections (protein regions).

Modulation of angiogenesis and wound healing

Methods of regulating angiogenesis, ischemic injury and / or wound healing by modulating the activity of leptin, particularly as mediated by the leptin receptor, and / or the interaction between leptin and the leptin receptor. Correspondingly, these methods can also be used to treat diseases mediated by angiogenesis, including wound healing, tumors and tumor metastasis, diabetic microangiopathy, retinal neovascularization, neovascularization of adipose tissue and fat metabolism, revascularization of necrotic tissue, enhancement or vascularization in microvascular transplants, and ovarian follicle maturation. Assays for identifying agents that modulate leptin and / or leptin receptor-mediated angiogenesis and / or wound healing and their use in treating angiogenesis-mediated diseases or conditions involving wound healing are also disclosed.
Owner:YALE UNIV

Methods and uses of leptin in immune modulation and hepatocellular carcinoma

Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×106 human Hep3B cells, followed by administration of two daily intraperitoneal doses of 0.5 mg / gram leptin for 6 weeks. Leptin administration induced a significant reduction in tumor size and improved survival in nude mice. Histologically, tumors of leptin-administered mice featured increased inflammatory exudate in interphase areas. Leptin-induced tumor suppression was associated with a significant increase in peripheral natural killer (NK) cell number. Splenocytes from leptin-treated mice featured decreased expression of CIS mRNA. To determine which lymphocyte subset is a prerequisite for the anti tumor effect of leptin, T&B cell deficient (Scid) mice and T,B& NK deficient (Scid-Beige) mice were subcutaneously implanted with Hep3B tumor cells, with and without the daily intraperitoneal administration of 0.5 mg / gram leptin for 6 weeks. SCID mice featured leptin-associated tumor suppression similar to those of nude mice. In contrast, NK-deficient SCID-Beige mice developed larger tumors. To further establish natural killer cell's central role in mediation of leptin's anti-tumor effect, NK cells were incubated in vitro with increasing doses of leptin, demonstrating a dose-dependent increase in cytotoxic activity. Incubation of leptin with hepatoma cell line was found to induce a dose-dependent reduction in hepatoma cell proliferation, suggesting an additive direct anti-tumor effect. Further synergism in inhibition of hepatoma cell proliferation in vitro was achieved following addition of natural killer cells. HCC cells expressed leptin receptor mRNA, while addition of leptin induced increased mRMA expression of STAT2 and SOCS1 on tumor cell lines. Leptin administration induces a significant suppression of human HCC. This effect is mediated by induction of natural killer cell proliferation and activation, and by direct inhibition of tumor growth. Decreased natural killer cell expression of inhibitory CIS protein and over expression of the anti-proliferative STAT2 and SOCS1 proteins in HCC lines may underline both anti cancerous effects of leptin.
Owner:ENZO THERAPEUTICS

High affinity leptins and leptin antagonists

Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.
Owner:THE MEDICAL RES INFRASTRUCTURE & HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENT +1

Method of treating, preventing, and diagnosing prostate cancer

A method of treating prostate cancer in a prostate cancer patient is disclosed. In one embodiment of the present invention, the method comprises the step of decreasing or blocking the patient's leptin interaction with leptin receptor or increasing adiponectin interaction with adiponectin receptors.
Owner:MCW RES FOUND INC

High affinity leptins and leptin antagonists

ActiveUS20130133089A1Increased level of blood blood glucoseIncreased level of blood insulin bloodCompounds screening/testingObesity gene productsAntagonistAvidity
Leptin muteins, in particular leptin antagonists, with increased binding affinity to leptin receptor are provided. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of any disorder in which a non-desirable or deleterious activity of endogenous leptin or an altered innate immune response is implicated.
Owner:THE MEDICAL RES INFRASTRUCTURE & HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENT +1

Kit for detecting soluble leptin receptor (sOB-R) by latex enhanced turbidimetric immunoassay

The invention relates to the field of in vitro diagnostic reagents and in particular relates to a kit for detecting a soluble leptin receptor (sOB-R) by latex enhanced turbidimetric immunoassay. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 is formed by a buffer solution 1, a stabilizing agent 1, a preservative 1, ethylene diamine tetraacetic acid (EDTA), a coagulant and a protective agent 1; the reagent R2 is formed by polystyrene latex microspheres crosslinked with an sOB-R antibody, buffer solutions 2, stabilizing agents 2, a preservative 2 and a protective agent 2; the polystyrene latex microspheres are connected with the sOB-R antibody by covalent crosslinking. The kit has the beneficial effects that latex enhanced turbidimetric immunoassay is adopted, and when the sOB-R in the blood reacts with the sOB-R antibody, polystyrene latexes are driven to gather to generate a certain turbidity, so that the kit is more convenient in detection and is easy to apply clinically.
Owner:ZYBIO INC

Leptin receptor agonist antibody for use in treating metabolic dysfunction or hypoleptinemia

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.
Owner:REGENERON PHARM INC

Methods of treatment using a leptin receptor agonist antibody

ActiveUS20190309079A1Relieve symptomsReverses or mitigates one or more of hyperphagiaMetabolism disorderPharmaceutical delivery mechanismDyslipidemiaAcute hyperglycaemia
Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.
Owner:REGENERON PHARM INC

Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders

InactiveUS20080058431A1Reducing and preventing undesiredHigh activityOrganic active ingredientsBiocideDiseaseHuman animal
Described are methods and compositions for regulating body weight and / or regulating the rate of weight gain or loss, and particularly, for treating or preventing obesity. Specifically, methods of administering varying levels of Shp2 modulators to an animal, alone or in combination with body weight regulating agents are disclosed. Methods and compositions for treating a variety of disorders associated with or caused by undesirable body weight are also described. Also described are methods for identifying compounds useful for regulation of body weight and associated conditions. In particular, methods are disclosed for identification of compounds that preferentially modulate binding of Shp2 to leptin receptors. Also described is a genetically modified non-human animal model for studying the peripheral and central pathways of energy homeostasis. Also disclosed are methods of identifying compounds for regulating such pathways.
Owner:THE BURNHAM INST

Functional fragment of the leptin receptor

InactiveUS7235629B2Modulated signalPeptide/protein ingredientsPeptide sourcesEphA ReceptorsSOCS3
The present invention relates to a functional fragment of a receptor having a function in signaling. Particularly, the present invention relates to a functional fragment of the leptin receptor, involved in SOCS3, CIS and / or Vav signaling.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW

Soluble leptin receptor (sOB-R) latex reinforced immunonephelometry assay kit by utilizing surface functional group

The invention relates to the field of in-vitro diagnostic reagents, and particularly relates to a soluble leptin receptor (sOB-R) latex reinforced immunonephelometry assay kit by utilizing a surface functional group. The assay kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 is prepared from a buffer solution 1, a stabilizing agent 1, a preservative 1, EDTA, a gelling agent and a protective agent 1; the reagent R2 is prepared from polystyrene latex microspheres crosslinked with an sOB-R antibody, a buffer solution 2, a stabilizing agent 2, a preservative 2 and a protective agent 2; the polystyrene latex microspheres and the sOB-R antibody are connected by means of covalent cross-linking; the surface functional group of the polystyrene latex microspheres in the reagent R2 is amino, carboxyl, hydrazide, aldehyde or epoxy group. According to the assay kit, a latex reinforced immunonephelometry method is adopted, when the sOB-R in blood reacts with the sOB-R antibody, polystyrene latex is driven to aggregate and generate certain turbidity, so that the detection can be convenient. The sOB-R latex reinforced immunonephelometry assay kit is easily applied in clinical application.
Owner:CHONGQING ZHONGYUAN BIOLOGICAL TECH

Ion stabilizing agent and suspension stabilizing agent cooperatively used kit for detecting sOB-R (soluble leptin receptor) by latex enhanced turbidimetric immunoassay

The invention relates to the field of in vitro diagnostic reagents and in particular relates to an ion stabilizing agent and suspension stabilizing agent cooperatively used kit for detecting a soluble leptin receptor (sOB-R) by latex enhanced turbidimetric immunoassay. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 is formed by a buffer solution 1, a stabilizing agent 1, a preservative 1, ethylene diamine tetraacetic acid (EDTA), a coagulant and a protective agent 1; the reagent R2 is formed by polystyrene latex microspheres crosslinked with an sOB-R antibody, buffer solutions 2, stabilizing agents 2, a preservative 2 and a protective agent 2; the polystyrene latex microspheres are connected with the sOB-R antibody by covalent crosslinking; the stabilizing agents 2 in the reagent R2 are an ion stabilizing agent and a suspension stabilizing agent, which are cooperatively used. The kit has the beneficial effects that latex enhanced turbidimetric immunoassay is adopted, and when the sOB-R in the blood reacts with the sOB-R antibody, polystyrene latexes are driven to gather to generate a certain turbidity, so that the kit is more convenient in detection and is easy to apply clinically.
Owner:CHONGQING ZHONGYUAN BIOLOGICAL TECH

Leptin receptor affinity peptide and application thereof

ActiveCN113248569AGood damage repair effectHigh affinityPeptidesProsthesisCollagen scaffoldTargeted therapy
The invention discloses an Leptin receptor affinity peptide and an application thereof. The sequence of the Leptin receptor affinity peptide is as shown in SEQ ID No.1. The invention further discloses an affinity peptide with collagen binding capacity. The affinity peptide comprises the Leptin receptor affinity peptide and a short peptide with specific collagen binding capacity, and the short peptide with the specific collagen binding capacity is bound to the N end of the Leptin receptor affinity peptide. The affinity peptide has high affinity with a Leptin receptor and can be specifically bound with MSC, the affinity peptide is connected to a biological material, and the affinity peptide connected with the short peptide with the specific collagen binding capacity can achieve specific binding with a collagen scaffold, so that the recruitment of the biological material on the MSC with the surface expressing the Leptin receptor is improved, a better tissue damage repair effect is obtained, and an experimental basis is provided for researching the MSC in the aspects of tissue engineering repair and targeted therapy research.
Owner:DUBU BIOSCIENCES

Cell-permeable (CP)-Δ SOCS3 recombinant protein and uses thereof

The present invention is related to development of the improved cell-permeable (CP)-ΔSOCS3 recombinant protein which disrupt the interaction of leptin receptor (ObR) and suppressor of cytokine signaling 3 (SOCS3), as protein-based anti-obesity or anti-diabetes agent by utilizing the platform technology for macromolecule intracellular transduction.
Owner:CELLIVERY THERAPEUTICS

Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof

The present invention relates to identification of a receptor for a satiety factor, which is involved in body weight homeostasis. Mutations in this receptor are associated with obese phenotypes. In particular, the present invention relates to identification and characterization of the receptor for leptin, including a naturally occurring soluble form of the receptor that is expected to modulate leptin activity, in particular to agonize leptin activity. The invention further relates to the nucleic acids encoding the receptor, and to methods for using the receptor, e.g., to identify leptin analogs, therapeutically, such as in gene therapy or in soluble form as an agonist or antagonist of leptin activity, or diagnostically.
Owner:THE ROCKEFELLER UNIV

Rutundic acid R as leptin sensitizer as well as application thereof in preparation of weight-reducing medicines

The invention provides a rutundic acid R as a leptin sensitizer as well as application thereof in preparation of weight-reducing medicines. The in-vitro mechanism studies show that the rotundic acid Rcan significantly reduce the food intake of a mouse fed with high fat diet (HFD) so as to reduce the weight of the mouse; and the weight reduction effect on normal lean mice and mice lacking leptin receptors are weak. Besides, the body fat of the HFD-fed mouse can be reduced obviously by the rotundic acid R; and the fat browning and expression of fatty acid oxidation genes can be promoted by activating the mitochondrial function and the browning of subcutaneous white fat of the mouse is accelerated. The phosphorylation of downstream STAT3 is promoted by possibly inhibiting the activity of PTP1B, so that the sensitivity of a leptin receptor is improved and thus the effect of reducing weight is realized.
Owner:PEKING UNIV

Nucleic acids db, the receptor for leptin

The present invention relates to identification of a receptor for a satiety factor, which is involved in body weight homeostasis. Mutations in this receptor are associated with obese phenotypes. In particular, the present invention relates to identification and characterization of the receptor for leptin, including a naturally occurring soluble form of the receptor that is expected to modulate leptin activity, in particular to agonize leptin activity. The invention further relates to the nucleic acids encoding the receptor, and to methods for using the receptor, e.g., to identify leptin analogs, therapeutically, such as in gene therapy or in soluble form as an agonist or antagonist of leptin activity, or diagnostically.
Owner:THE ROCKEFELLER UNIV

Application of s100a11 protein as a diabetes biomarker and therapeutic target

The present invention provides the application of S100A11 protein as a diabetes biomarker and therapeutic target. The present invention studies the expression of S100A11 in leptin receptor deficient (db / db) spontaneous diabetic mice, and finds that S100A11 protein can promote Insulin resistance, increased accumulation of lipid droplets in the liver and increased liver and fat weight. After the inventors compared the control group and the experimental group, there was a significant difference in the expression level of S100A11. Therefore, S100A11 can be used as a marker for diabetes diagnosis, prognosis assessment or drug screening.
Owner:SOUTHERN MEDICAL UNIVERSITY

A sob-r latex enhanced immunoturbidimetric detection kit utilizing surface functional groups

The invention relates to the field of in-vitro diagnostic reagents, and particularly relates to a soluble leptin receptor (sOB-R) latex reinforced immunonephelometry assay kit by utilizing a surface functional group. The assay kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 is prepared from a buffer solution 1, a stabilizing agent 1, a preservative 1, EDTA, a gelling agent and a protective agent 1; the reagent R2 is prepared from polystyrene latex microspheres crosslinked with an sOB-R antibody, a buffer solution 2, a stabilizing agent 2, a preservative 2 and a protective agent 2; the polystyrene latex microspheres and the sOB-R antibody are connected by means of covalent cross-linking; the surface functional group of the polystyrene latex microspheres in the reagent R2 is amino, carboxyl, hydrazide, aldehyde or epoxy group. According to the assay kit, a latex reinforced immunonephelometry method is adopted, when the sOB-R in blood reacts with the sOB-R antibody, polystyrene latex is driven to aggregate and generate certain turbidity, so that the detection can be convenient. The sOB-R latex reinforced immunonephelometry assay kit is easily applied in clinical application.
Owner:CHONGQING ZHONGYUAN BIOLOGICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products